Ophthorobotics
Ophthorobotics AG is a preclinical-stage medtech company focused on developing a robotic-assisted system for intravitreal injections, aiming to enhance safety, efficiency, and quality in treating ocular diseases. Their innovative approach addresses significant challenges in current treatment methods, such as human error and inefficiencies, by providing a fully automated injection system that integrates advanced technology for precise and safe procedures. With a growing market for intravitreal therapies, particularly for age-related macular degeneration, Ophthorobotics is positioned to lead in this space, supported by a strong patent portfolio and a commitment to improving patient outcomes.
Ophthorobotics
Ophthorobotics AG is a preclinical-stage medtech company focused on developing a robotic-assisted system for intravitreal injections, aiming to enhance safety, efficiency, and quality in treating ocular diseases. Their innovative approach addresses significant challenges in current treatment methods, such as human error and inefficiencies, by providing a fully automated injection system that integrates advanced technology for precise and safe procedures. With a growing market for intravitreal therapies, particularly for age-related macular degeneration, Ophthorobotics is positioned to lead in this space, supported by a strong patent portfolio and a commitment to improving patient outcomes.
TL;DR
Stage: Preclinical
Lead product: IID automated intravitreal injection system
Founded: 2015
Headquarters: Zurich, Switzerland
Key IP: European patent for delivery system (coverage reported through 2043)
Company Overview
Problem Domain
Ophthalmic drug delivery, specifically intravitreal injections
Founded
2015
Industry
Biotechnology
Funding Track Record
30372
Grant funding reported; multiple grant rounds noted in profiles.
Investor Signal
“Preparing for Series A to enter clinical trials (as announced in company materials)”